-->

Tech Seeker (TS)

Paladin Labs Inc
Profile last edited on: 3/22/2022

Specialty pharmaceutical company
TS Type
Small firm: Foreign
Status
Active
Year Founded
1983
Last Involved Year
2003

Key People / Management

Location Information

100 Boulevard Alexis Nihon Suite 600
St. Laurent, QC H4M 2P2
   (514) 340-1112
   www.paladinlabs.com

Public Profile

Paladin Labs, Inc., a specialty pharmaceutical company, focuses on the development, acquisition, in-licensing, marketing, and distribution of pharmaceutical products. The Company's product portfolio includes Tridural, Abstral and Trelstar. Tridural is a once-a-day tramadol product indicated as a first-line therapy for adults with moderate pain requiring several days or more of treatment. Abstral is a sublingual tablet used for the management of breakthrough cancer pain in patients who are already tolerant to other opioid analgesics. Trelstar is an injectable, luteinizing hormone releasing hormone agonist indicated for the palliative treatment of prostate cancer and endometriosis. In February 2011, the Company acquired the Tempra line of products in Canada from Bristol-Myers Squibb. In November 2011, it acquired the rights to Travelan in Canada, Latin America and Sub-Saharan Africa. Effective January 1, 2013, the Company acquired Ativa Pharma S.A.. Paladin's products include Impavido, which is used to treat leishmaniasis; Dexedrine that is used to treat attention deficit hyperactivity disorder and narcolepsy; Sancuso, which is used to treat nausea and vomiting in patients undergoing chemotherapy; Abstral, Tridural, and Metadol, which are dissolving sub-lingual tablets of fentanyl that manage cancer pain in patients who are already receiving opioid analgesics; Pennsaid, a lotion for the treatment of symptoms of knee osteoarthritis; Trelstar that manages prostate cancer; Testim, a topical testosterone gel indicated for testosterone replacement therapy in adult males; Twinject, a dual dose epinephrine for anaphylactic patients; and Seasonique and Plan B, which are oral contraceptives. The company also offers Hepatitis B and C vaccines, as well as other products that treat liver, ovarian, and other cancers. In addition, it focuses on the development of Oralair, a desensitization tablet for the treatment of allergic rhinitis; and Glide Octreotide Solid Dose Injector, a peptide that is used in the treatment of acromegaly and neuroendocrine tumors. Further, the company provides dissolving edible films for pharmaceutical and nutraceutical markets, as well as offers over-the-counter drugs, such as Unisom and Kaopectate. Paladin Labs, Inc. primarily focuses on women's health, urological disorders, and pain treatment. The company serves pharmaceutical wholesalers and chain pharmacies. It has a development agreement with Sylphar N.V. to develop and market an oral dissolving teeth whitening film strip in Europe. The company was formerly known as GeriatRx and changed its name to Paladin Labs, Inc. in June 1995.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
Canada
Employment
126
Revenue
$0.2B
Public/Private
Publicly Traded
Stock Info
TSE Toront : PLB
Received SBIR $$
No

SBIR firms in the news

There are no news available.